Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation

NCT02458417 is registered in ClinicalTrials.gov with Netherlands Institute for Pigment Disorders as lead sponsor.

NCT NCT02458417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02458417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation
Lead sponsor
Netherlands Institute for Pigment Disorders
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2015
Completion date
January 31, 2016
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

piebaldism, segmental vitiligo